Results 161 to 170 of about 24,005 (199)

Disproportionality analysis of taste disorders using the FDA adverse event reporting system and Japanese adverse drug event report databases. [PDF]

Front Pharmacol
Kyotani Y, Nakahira K, Yoshizumi M.
europepmc   +1 more source

A Phase I/IB, Open Label, Dose Finding Study to Evaluate Safety, Pharmacodynamics and Efficacy of Pembrolizumab in Combination With Vorinostat in Patients With Advanced Prostate, Renal or Urothelial Carcinoma. [PDF]

Cancer Med
Pili R, Quinn DI, Adra N, Logan T, Colligan S, Burney HN, Hahn NM.   +6 more
europepmc   +1 more source

Systematic profiling of cancer-fibroblast interactions reveals drug combinations in ovarian cancer. [PDF]

Mol Oncol
Gudoityte G, Sharma O, Leuenberger L, Wallin E, Fernebro J, Östling P, Bergström R, Lindberg J, Joneborg U, Kallioniemi O, Seashore-Ludlow B.   +10 more
europepmc   +1 more source

Targeting Latent HIV Reservoirs: Effectiveness of Combination Therapy with HDAC and PARP Inhibitors. [PDF]

Viruses
Tibebe H, Marquez D, McGraw A, Gagliardi S, Sullivan C, Hillmer G, Narayan K, Izumi C, Keating A, Izumi T.   +9 more
europepmc   +1 more source

Enhancing venetoclax efficacy in leukemia through association with HDAC inhibitors. [PDF]

Cell Death Discov
Carlos JAEG, Tavares MT, Lima K, de Almeida LC, de Barros Waitman K, Costa-Lotufo LV, Parise-Filho R, Machado-Neto JA.   +7 more
europepmc   +1 more source

Three novel epigenetic-modifying compounds identified as HIV latency-reversing agents in Ghana

Abana CZ, Boateng AT, Abaidoo-Myles A, Nartey PA, Bortey CB, Quansah DNK, Aboagye JO, Appiah-Opong R, Quaye O, Clark KM, Lamptey H, Shan L, Bonney EY, Kyei GB.   +13 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Lapatinib: Vorinostat

Hospital Pharmacy, 2007
The increasing complexity of cancer chemotherapy increases the requirement that pharmacists be familiar with these highly toxic agents. This column will review various issues related to preparation, dispensing, and administration of cancer chemotherapy, and review various agents, both commercially available and investigational, used to treat malignant
Daniel C. McHugh, Dominic A. Solimando, J. Aubrey Waddell   +2 more
openaire   +1 more source

Safety and tolerability of vorinostat—Experience from the vorinostat clinical trial program

Journal of Clinical Oncology, 2008
14580 Background: Vorinostat is a histone deacetylase inhibitor with anticancer properties when used alone or in combination.
D. S. Siegel, M. A. Hussein, C. P. Belani, F. Robert, S. Rizvi, J. Wigginton, S. Randolph, R. Crane, R. Ganesan, J. Garcia-Vargas   +9 more
openaire   +1 more source

Vorinostat in cutaneous T-cell lymphoma

Drugs of Today, 2007
Histone deacetylase inhibitors (HDAC-Is) are a novel class of small molecules being evaluated in clinical trials for a number of different malignancies. HDAC-Is are able to induce differentiation, apoptosis and/or cell cycle arrest of malignant cells selectively.
Madeleine, Duvic, Jenny, Vu
openaire   +2 more sources

Vorinostat

Reactions Weekly, 2015
  +4 more sources